Generali Asset Management SPA SGR Buys 32,174 Shares of Edwards Lifesciences Corporation $EW

Generali Asset Management SPA SGR raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 79.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,539 shares of the medical research company’s stock after buying an additional 32,174 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Edwards Lifesciences were worth $6,184,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter worth $25,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $28,000. Dorato Capital Management purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $29,000. N.E.W. Advisory Services LLC raised its stake in shares of Edwards Lifesciences by 533.9% during the 4th quarter. N.E.W. Advisory Services LLC now owns 374 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 315 shares during the period. Finally, Rakuten Securities Inc. lifted its holdings in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,816,861.34. This represents a 2.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 88,096 shares of company stock worth $7,288,799. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Evercore restated an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. The Goldman Sachs Group reiterated a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. BTIG Research raised their price objective on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Wednesday, April 1st. Finally, Robert W. Baird upped their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $95.65.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $79.86 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 4.42. The stock has a market cap of $45.98 billion, a P/E ratio of 42.48, a price-to-earnings-growth ratio of 2.08 and a beta of 0.87. The firm’s fifty day moving average price is $82.16 and its 200-day moving average price is $82.74.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.